Portfolio for the
2 | Drug Discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging
Expertise across the entire value chain
At BASF, we know that innovation, speed-to-market, and What’s more, we foster effective collaboration and know-
cost-effectiveness are key to pharmaceutical companies. ledge transfer between the teams responsible for our
With our comprehensive portfolio and unparalleled skills at various products and services. So when you partner with
every stage of the pharmaceutical value chain, we pro- us, you can count on truly end-to-end expertise.
vide the support you need to deliver on all three counts.
Drug Discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging
Our offerings focus on specific phases of the pharmaceutical value chain – but are usually not confined to one phase.
Focused on your needs
BASF provides products and services for the pharmaceut- not only a reliable and efficient supplier of standard prod-
ical industry that enhance your competitiveness. We ucts; we are also a trusted partner when it comes to
focus firmly on meeting your needs. As a result, BASF is developing tailor-made solutions and processes.
We continuously extend and enhance our range of products and services.
2000 2003 2006
BASF builds its first biocatalysis plant Acquisition of Callery Chemical Acquisition of Engelhard – the
in Ludwigshafen, producing ChiPros® – the expert in boron and alkali expert in catalysts; making
– high-quality chiral amines metal reagents BASF the largest catalyst pro-
Foundation of metanomics Health Acquisition of Orgamol – a
(BASF affiliate) – the specialist in company with half a century of
metabolite profiling experience and expertise in
Drug Discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging | 3
Leading the way in innovation Ensuring high quality standards
Our success – and yours – is built on research and innov- Consistently high quality is our top priority – and not just
ation. At BASF, that means more than just new products; because pharmaceutical production is subject to strin-
it also encompasses enhanced processes. Around 8,300 gent regulations. We also have our own rigorous internal
BASF specialists worldwide leverage our extensive ex- standards.
perience and expertise to conduct ongoing R&D across
Our manufacturing facilities are certified to ISO 9001 and
virtually all chemical disciplines.
fulfill current Good Manufacturing Practice (cGMP) stand-
Interdisciplinary and international collaboration, including ards, where required. They are regularly inspected by
cooperation with external partners, such as universities national and international authorities, including the US Food
and industry players, helps ensure we remain at the lead- and Drug Administration (FDA).
New European chemicals legislation (REACH) places even
greater demands on companies with regard to product
Verbund – the power of networking stewardship and information on substance safety. To help
BASF’s Verbund is one of our greatest assets when it you achieve REACH compliance, BASF has pooled its skills
comes to getting the best out of our resources. Our Pro- in EU chemicals legislation, and offers made-to-measure
duction Verbund links our individual plants, enabling us to service packages.
create efficient and reliable value chains – ranging from
basic chemicals through to end-user products. We also
apply the Verbund principle to our research and know-
ledge management, and to teamwork among BASF em-
ployees. Pharma experts from all BASF divisions share
their knowledge to generate new ideas – and work hand
in hand with you to develop solutions that create value for
At BASF, we leverage a wide range of technologies and reactions.
Acetylene chemistry Carbonylation HCN chemistry Organometallic chemistry
Alkoxylation C-C coupling Heterogeneous catalysis Organylzinc chemistry
Amination Chinoline synthesis High-pressure reactions Oxamination
Asymmetric borane reduction Chlorination Hydrazine chemistry Phosgene chemistry
Asymmetric hydrogenation Chloromethylation Hydroformylation Phosphorous chemistry
Asymmetric synthesis Cryogenic reactions Hydrogenation Photochemistry
Azide chemistry Electrochemistry Ionic liquid technologies Polymerization (all types)
Biotransformations Enzyme technologies N-, O-Heterocycles synthesis Suzuki coupling
Bromination Grignard reactions Olefin/Polyene chemistry Wittig reaction
The following pages provide an overview of our portfolio. For further details, check out the enclosed CD.
4 | Drug discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging
Metabolite Profiling Catalysts
metanomics Health, a BASF affiliate, applies metabolite At BASF, we continuously apply our expertise in surface
profiling to identify and apply biomarkers for drug discovery and material science to develop new catalytic technolo-
and development, diagnostics, and nutritional research. gies. Our state-of-the-art precious-metal deposition tech-
This supports and accelerates various phases of the drug nologies allow us to fine-tune formulations to the specific
development chain by reducing risk and increasing efficacy needs of our customers’ chemistry and equipment. Our
and response rates. comprehensive precious-metal services enable you to
focus on metal application, and not on non-value-added
services (e.g. transit or recovery).
Drug development and toxicology
• Early identification and classification of What we offer:
toxicity mode of actions A comprehensive portfolio of homogeneous and hetero-
• Increased mechanistic understanding geneous catalysts for fine-chemical applications
• Identification of biomarkers for efficacy A wide range of selective (precious-metal) adsorbents
and pharmacology Deep understanding of customers’ processes and needs
• Support for compound ranking and decision-making Global manufacturing and R&D resources
• Stratification of patients One of the broadest offerings of customized base-metal
• Differentiation of responders and non-responders and precious-metal catalysts available
Disease diagnostics and prognostics Full-loop precious-metal services and
The best technical service in the business
Toxicology metabolome database for prediction www.catalysts.basf.com/pharma
Drug Discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging | 5
BASF’s portfolio includes organic reagents and inorganic BASF produces high-quality solvents that meet the specific
specialty reagents (e.g. MeCBS), various boranes, specialty needs of the pharmaceutical industry. We also offer com-
bases and organozinc building blocks, as well as chiral prehensive packages of auxiliary services and newly de-
amines that facilitate reactions with high selectivity. To veloped solutions for selected products. An outstanding
support your development work from lab to launch, all example is our THF Pharma super dry, which has an ex-
reagents are available in quantities from kilograms to tons. tremely low water content (50 ppm), and is the solvent of
choice for many water-sensitive reactions.
Chiral amines Selected products:
Diazabicycloundecene (DBU) N,N’-Dimethylpropylene urea (DMPU)
Triphenylphosphine (TPP) N-Methylpyrrolidone (NMP)
Triethylamine Tetrahydrofuran pharma (THF)
Piperidine Dimethylformamide (DMF)
Hünig base N,N-Dimethylacetamide (DMAC)
Formic acid Dioxane
Inorganic Specialty Reagents
Alkali metal alcoholates
Alkali amides Protective Groups
Hydroxylamine and derivatives
Boron trifluoride (complexes) In numerous complex synthesis routes for APIs, some
Organozinc reagents functional groups have to be shielded against conversion
Borane complexes in a specific reaction step. For this purpose, BASF offers a
Amine boranes range of compounds that provide the necessary protection
Chiral boranes in your transformations. Various types of functions, ranging
Alkylboranes from alcohols to amines, can be protected.
Suzuki coupling reagents
Dr. Daniela Proske is a firm believer in the power of Benzophenone imine
When her customer - the US subsidiary of a European-based
pharmaceutical company - requested a catalyst to optimize the
production process, Dr. Daniela Proske, a BASF expert in inter-
mediates, knew exactly who to call: her Dutch colleague, Dr. Jim
Brandts, at the Catalysts division. He designed a new type of cata-
lyst, which was supplied from the catalyst plant in the US. And
when the customer transferred development and scale-up to
Europe, the Catalysts division followed suit, moving activities to
Rome. What’s more, when commercial production got underway
at the customer’s Asian plant, local BASF staff were on hand to
manage catalyst shipments.
6 | Drug Discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging
Building Blocks Custom Synthesis
BASF’s innovative technology platform and our extensive BASF produces customized active ingredients and ad-
expertise in biocatalysis enable us to manufacture a wide vanced intermediates exclusively on behalf of pharma-
range of building blocks. Our offerings include a large ceutical companies – and in complete confidence. Our
number of chiral intermediates and non-chiral specialties, experts offer support throughout the drug lifecycle: from
e.g. heterocycles and acid chlorides. Under the ChiPros® kilo laboratory to commercial production, from the early
trademark, BASF provides the world’s most extensive clinical phase to market launch, and even when the drug
portfolio of chiral amines, alcohols, acids and epoxides – becomes generic. When you join forces with our team, you
a portfolio that is steadily growing. Through the develop- benefit from an extensive range of skills and technologies.
ment of tailor-made building blocks, we can assist your
Over 600 m3 cGMP-compliant reactor capacity in
drug discovery process from the early stages to launch.
ChiPros®: e.g. R-2-Chloromandelic acid, S-Phenyl- Saint-Vulbas (France)
propylamine, R-Styrene oxide Ludwigshafen and Minden (Germany)
Heterocycles: e.g. piperazine, imidazoles, pyrrols, www.pharma-ingredients.basf.com/custom-synthesis
Dr. Raphaël Gabioud and his colleagues know the value of teamwork.
Specialty amines: e.g. 2,6 Xylidine, tert. butylamine, Dr. Raphaël Gabioud, an expert in custom synthesis at BASF, was tasked
3-Amino-1-propanol, pyrrolidine, methoxypropylamine, with enhancing the production process for an advanced intermediate used
dimethylaminopropanol in a complex API. He soon realized the synthesis route could be improved by
greater selectivity. Moreover, he knew that the necessary chiral amine could
www.pharma-intermediates.basf.com be developed by our in-house specialists – Prof. Dr. Klaus Ditrich and his
team. By drawing on BASF’s unique global network of skills and resources,
he was able to offer the customer a tailor-made solution to his needs.
Drug Discovery > Preclinical Studies > Clinical Phases I-III > API Manufacturing > Drug Formulation > Packaging | 7
Plastics for Healthcare
Generic APIs & Diagnostics*
BASF provides generic active ingredients for many thera- BASF provides four different high-performance plastics for
peutic fields of application, and is the market leader in the healthcare and diagnostics market (HD). What’s more,
caffeine, ibuprofen, pseudoephedrine and theophylline. we offer services and assurances that are unparalleled in
Moreover, BASF offers a broad portfolio of smaller volume the industry.
Selected applications Terlux® HD (MABS)
Analgesics Terluran® HD (ABS)
Anesthetics Luran® HD (SAN)
Nervous system Ultraform® PRO (POM)
www.pharma-ingredients.basf.com/active-ingredients Valves, springs and sliding elements
Our service package for the healthcare and diagnostics
industry includes an undertaking not to change the resin
Excipients formulation – as defined in the Drug Master File (DMF) –
or, where such changes are necessary, to announce them
When it comes to a broad portfolio of excipients with ex- at least three years in advance. BASF also tests the com-
ceptional potential, it’s hard to surpass BASF. The product patibility of its plastics with specific chemicals, and helps
spectrum – particularly the Kollidon® and Kollicoat® ranges customers gain relevant approvals worldwide.
– fulfills all the functional and regulatory requirements for
excipients used in the production of tablets, sprays or drops.
Protect your brands and consumers’ health – by lever-
aging BASF’s extensive experience in safeguarding prod-
ucts, banknotes and documents.
Excipients for orally disintegrating tablets
Solubilizers, solvents and cosolvents We offer
Customer-specific security levels
Overt and covert solutions
Guaranteed confidentiality and supply-chain security
* BASF has not designed or tested its plastics with respect to all of the special requirements re- Packaging applications include
lated to their use in medical devices and pharmaceutical applications. Therefore, BASF makes
no warranties concerning the suitability of any BASF plastics for use in any medical device Board
and pharmaceutical applications. Subject to an evaluation and a release in each individual case
and, if necessary, acceptance of a disclaimer by the customer, BASF is in general prepared to Labels
supply plastics for medical applications. However, BASF does not supply its plastics for the
manufacture of implants in any risk class. In all cases the BASF customers have to establish Leaflets
from their own experience and from tests on BASF plastics, that these plastics are suitable for
the manufacture of products for medical applications or pharmaceutical applications and the Printing inks
customers have to ensure that the medical device or pharmaceutical application manufactured
using BASF plastics is safe, lawful and technically suitable for the intended use. Coatings
BASF is close to you – all around the globe
● metanomics Health
● cGMP Sites (e.g. APIs,
Excipients, ChiPros®, De Meern Minden
Custom Synthesis) Beachwood
St. Vulbas Evionnaz
● Chemicals (e.g. Building Blocks, Evans City
Washington, D.C. Rome Ulsan
Reagents, Catalysts, Solvents) Geismar Nanjing
■ Technical Service Centers/R&D sites Shanghai
Metabolite Profiling Organic Reagents, Solvents, Building Excipients
Dr. Kristina Busch Blocks, Protective Groups Dr. Hubertus Folttmann
+49 30 3480-7121 Dr. Martin Merger +49 621 60-28560
email@example.com +49 621 60-44614 firstname.lastname@example.org
Catalysts Plastics for Healthcare & Diagnostics
Tiny Koelewijn Custom Synthesis Marcela Villegas
+31 30 666-9309 Dr. Folker Ruchatz +49 621 60-45264
email@example.com +41 27 766-1220 firstname.lastname@example.org
Inorganic Specialty Reagents Anti-Counterfeiting
Dr. Felix Görth Generic APIs Szymon Siuda
+1 724 538-1317 Brigitte Sebastian +49 621 60-43062
email@example.com +41 27 766-1612 firstname.lastname@example.org
BASF is the world’s leading chemical company: The Chemical Company.
Its portfolio ranges from oil and gas to chemicals, plastics, performance
products, agricultural products and fine chemicals. As a reliable partner
® = Registered Trademark of BASF
BASF helps its customers in virtually all industries to be more successful.
With its high-value products and intelligent solutions, BASF plays an im-
Last update: August 2008
portant role in finding answers to global challenges such as climate protec-
tion, energy efficiency, nutrition and mobility.
Further information on BASF is available on the Internet at:
This document, or any answers or information provided herein by BASF, does not constitute a legally binding obligation of BASF. While the descriptions, designs, data and information contained herein are presented in good faith
and believed to be accurate, it is provided for your guidance only. Because many factors may affect processing or application/use, we recommend that you make tests to determine the suitability of a product for your particular
purpose prior to use. It does not relieve our customers from the obligation to perform a full inspection of the products upon delivery or any other obligation.
NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARE MADE REGARDING PRODUCTS DESCRIBED OR DESIGNS,
DATA OR INFORMATION SET FORTH, OR THAT THE PRODUCTS, DESIGNS, DATA OR INFORMATION MAY BE USED WITHOUT INFRINGING THE INTELLECTUAL PROPERTY RIGHTS OF OTHERS. IN NO CASE SHALL THE DESCRIPTIONS,
INFORMATION, DATA OR DESIGNS PROVIDED BE CONSIDERED A PART OF OUR TERMS AND CONDITIONS OF SALE. (August 2008).